Latest Chemotherapeutic agents Stories
A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease.
RIDGEFIELD, Conn., Oct. 11 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.
EMERYVILLE, Calif., Oct. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that management will host a teleconference to provide a status update on its New Drug Application (NDA) for carfilzomib.
BURLINGTON, Mass., Sept.
EMERYVILLE, Calif., Sept. 16 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 3:00 p.m. Eastern Time (12:00 p.m.
LONDON and NEW YORK, Sept. 15 /PRNewswire/ -- Spirogen Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic Therapeutics") announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer.
EMERYVILLE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd.
EMERYVILLE, Calif., Sept. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:20 a.m. Eastern Time (7:20 a.m.
Researchers have identified a new target for the treatment of lymphoma and are testing a potential new drug in pet dogs afflicted with the disease.
A protein that plays a key role in regulating the onset of cell division has been identified as a potential target for the treatment of ovarian cancer.
- totally perplexed and mixed up.